Abdel-Moneim A, et al. - Authors resolved to clarify the retreatment efficacy and safety of the recent regimen, sofosbuvir (SOF) with paritaprevir, and ritonavir (OBV/PTV/r) + ribavirin (RBV), for chronic hepatitis C virus (HCV) genotype 4 (GT4)-experienced patients who failed treatment with direct-acting antiviral agent (DAA)-based regimens. It was determined that the recent multi-targeted regimen of SOF plus OBV/PTV/r + RBV was well tolerated. It illustrated excellent sustained virological response (SVR) rates among retreatment-experienced Egyptian patients with prior DAA treatments failure. Hence, an alternative regimen was obtained for the retreatment of difficult-to-cure HCV GT4 patients.